Destiny Pharma: Positive update on microbiome therapeutic NTCD-M3 for recurrent C. difficile infections

Positive update on microbiome therapeutic NTCD-M3 for recurrent C. difficile infections

· Preparations for Phase 3 study progressing to plan
· Established world leading clinical advisory board
· Partnering discussions ongoing

Brighton, United Kingdom – 2nd June 2021 – Destiny Pharma plc (AIM: DEST), a clinical stage innovative biotechnology company focused on the development of novel medicines that can prevent life threatening infections, is pleased to announce positive progress with its lead clinical programme, NTCD-M3.

Read more

By Optimum

For more information about Optimum Strategic Communications, please get in touch

We'd love to hear from you...

GET IN TOUCH